AXSM

Axsome Therapeutics Inc (AXSM) | Rumor.io

Axsome Therapeutics

AXSM

Attention (50-day avg)0%

Attention rank (50-day avg)#876

Bullish sentiment (50-day avg)83%

Price to earnings ratio-52.7

Market capitalization10.2B

Earnings per share-3.75

Dividend yield (TTM)—

Revenue (annual)638.5M

Net income (annual)-183.2M

Social

What share of all stock conversation is about AXSM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.01% +0	0% +0	0% 0

Sep 29

Axsome Therapeutics' management is being questioned for its handling of the stock, with some investors calling for a more aggressive approach to creating shareholder value, including cutting unnecessary spending, buying back shares, and providing more transparency on ADA data.
The stock's performance has been affected by uncertainty around the company's growth prospects, particularly in the ex-US AUVELITY market and the long-term care (LTC) segment.
Institutional ownership of Axsome Therapeutics has been growing, with some investors taking a long-term view and adding to their positions despite the stock's recent decline.

Generated by AI

Sentiment

Of the messages about AXSM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	55.56% -44.44	66.41% -28.79	82.51% -1.54	89.26% +1.6
Bearish	44.44% +44.44	33.59% +28.79	17.49% +1.54	10.74% -1.6

Bullish· Sep 23

Axsome Therapeutics' pipeline explores reformulations of known products in disease states complementary to its existing commercial infrastructure, which lowers clinical risk and has the potential for cost synergies.
The company's near-term revenue growth is expected to be positive, with a clinically de-risked pipeline and strong sales performance, outrunning estimates.
Axsome Therapeutics has a strong financial performance, with trailing revenue of $777M, up 57% YoY, and 93% gross margins, and a potential for significant upside with a +56% price target from Mizuho.

Bearish· May 4

The price target for $AXSM has been set at $275.00 by Jefferies.
The analysts' "yes" and market makers' "no" response to the ER has led to a disappointing market reaction.
The company's revenue is expected to double by this time next year, with the potential for ex-US sales to further boost the stock.

Generated by AI

Topics

Of the messages about AXSM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	63.33%	16.17%	31.18%
Announcements	0%	5%	72.39%	8.44%
Earnings	0%	6.67%	4.48%	1.38%
Technical Analysis	100%	25%	6.97%	30.09%
Controversies	0%	0%	0%	0.19%
Macro	0%	0%	0%	28.71%

Earnings· May 4

Axsome Therapeutics reported Q1 2026 earnings with a revenue beat of $191.2M, a 57% year-over-year increase, but an adjusted EPS miss of $(1.26), down 85% year-over-year.
The company's strong revenue momentum is driven by Auvelity, with a major label expansion in Alzheimer's agitation expected to boost peak sales to $3-4B.
Axsome's cash burn and widening losses raise questions about the company's long-term prospects, despite a recent 20% price jump and strong institutional buying interest.

Analysts· Aug 10

Morgan Stanley downgraded Axsome Therapeutics to Equal-Weight, lowering the price target from $105 to $34.
Truist Securities maintained a Buy rating, but lowered the price target from $200 to $160.
Analysts remain confident in Axsome Therapeutics, with a 93% buy consensus, and multiple firms have maintained their Buy ratings despite lowering price targets.

Announcements· May 1

Axsome Therapeutics' Auvelity has received FDA approval for the treatment of agitation associated with dementia due to Alzheimer's disease.
This is a significant milestone, as Auvelity is the first non-antipsychotic treatment approved for this condition, addressing a major unmet need.
The approval has sent Axsome Therapeutics' stock price soaring, with a 12% increase in afternoon trading, and analysts projecting peak sales of over $2.1 billion.

Controversies· May 18

Glancy Prongay & Murray LLP, a securities fraud law firm, is investigating Axsome Therapeutics, Inc. (AXSM) on behalf of investors, suggesting potential legal action.
A video discusses Axsome Therapeutics Securities Class Action, providing information and explanations that may be helpful to investors.
The firm's investigation and the video's content may indicate ongoing controversy and potential issues surrounding Axsome Therapeutics, Inc. (AXSM).

Technical Analysis· Aug 22

$AXSM has shown a strong follow-through on its breakout, touching 64 from 55 and retesting.
The stock is currently sitting under the $60 whole number, which could be used as a pivot, and has seen high volume, including 10x average volume.
Technical indicators such as RSI, MACD, and MA200 are aligned, suggesting a potentially strong move to 67-70 area this week.

Generated by AI

Community

Of the messages about AXSM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	92.65%	90.02%	87.1%	58.99%
Newcomers	7.35%	9.98%	12.9%	41.01%

Regulars· Sep 29

Regular investors are expressing frustration with Axsome Therapeutics' management, citing volatility and lack of confidence in the company's multibillion-dollar franchise potential, and are calling for a buyback and better ADA data disclosure.
The stock's recent decline is being attributed to a combination of factors, including rotation out of pharma companies and a lack of visibility into revenue estimates for Auvelity, with some investors speculating that an offering may be imminent.
Despite the decline, some investors remain optimistic, citing the growth in institutional ownership, with institutions adding shares rather than exiting their positions, and are urging others to have faith in the system and be patient.

Newcomers· May 5

Many newcomers are excited about the 12% increase in stock price after the Q1 2026 financial results were announced.
Some are focusing on the company's Q1 2026 financial results and business update, noting a positive trend in the stock price after the announcement.
Others are highlighting the stock's high price level and active volume, suggesting that it is a strong biotech name to watch.

Generated by AI

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has a market

5d agoBenzinga

10 Health Care Stocks Whale Activity In Today’s Session - Oruka Therapeutics (NASDAQ:ORKA), Axsome Therap

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

6d agoBenzinga

Truist initiates Axsome stock coverage with buy rating on growth

7d agoInvesting.com

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

9d agofinance.yahoo.com

Also Discussed

Investors talking about AXSM also mention

#	Name	Attention
1	Relmada Therapeutics Inc.RLMD	0%0
2	ITCI - Intra-Cellular Therapies, Inc.	——
3	MYOV - Myovant Sciences Ltd.	——
4	SWTX - SpringWorks Therapeutics, Inc.	——
5	SAGE - Sage Therapeutics, Inc.	——
6	KRTX - Karuna Therapeutics, Inc.	——
7	AVDL - Avadel Pharmaceuticals plc	——
8	TG Therapeutics Inc.TGTX	0.01%+0
9	BioXcel Therapeutics, Inc.BTAI	0%new
10	MRTX - Mirati Therapeutics, Inc.	——

Axsome Therapeutics Inc

Healthcare
Biotechnology

Axsome Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. Its marketed products include Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea, and Symbravo for the acute treatment of migraine. The company also maintains a neuroscience pipeline spanning additional neurological and psychiatric conditions, reflecting its emphasis on disorders with limited treatment options. Axsome Therapeutics Inc. plays a specialized role in the healthcare market by combining commercial products with ongoing clinical development in psychiatry, sleep medicine, pain, and migraine care. Based in New York, the company is positioned as a focused CNS innovator serving patients, physicians, and healthcare systems with therapies designed to address unmet medical needs.

Website

Location

One World Trade Center

New York, NY, 10007

United States

Social

What share of all stock conversation is about AXSM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.01% +0	0% +0	0% 0

Sep 29

Axsome Therapeutics' management is being questioned for its handling of the stock, with some investors calling for a more aggressive approach to creating shareholder value, including cutting unnecessary spending, buying back shares, and providing more transparency on ADA data.
The stock's performance has been affected by uncertainty around the company's growth prospects, particularly in the ex-US AUVELITY market and the long-term care (LTC) segment.
Institutional ownership of Axsome Therapeutics has been growing, with some investors taking a long-term view and adding to their positions despite the stock's recent decline.

Generated by AI

Sentiment

Of the messages about AXSM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	55.56% -44.44	66.41% -28.79	82.51% -1.54	89.26% +1.6
Bearish	44.44% +44.44	33.59% +28.79	17.49% +1.54	10.74% -1.6

Bullish· Sep 23

Axsome Therapeutics' pipeline explores reformulations of known products in disease states complementary to its existing commercial infrastructure, which lowers clinical risk and has the potential for cost synergies.
The company's near-term revenue growth is expected to be positive, with a clinically de-risked pipeline and strong sales performance, outrunning estimates.
Axsome Therapeutics has a strong financial performance, with trailing revenue of $777M, up 57% YoY, and 93% gross margins, and a potential for significant upside with a +56% price target from Mizuho.

Bearish· May 4

The price target for $AXSM has been set at $275.00 by Jefferies.
The analysts' "yes" and market makers' "no" response to the ER has led to a disappointing market reaction.
The company's revenue is expected to double by this time next year, with the potential for ex-US sales to further boost the stock.

Generated by AI

Topics

Of the messages about AXSM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	63.33%	16.17%	31.18%
Announcements	0%	5%	72.39%	8.44%
Earnings	0%	6.67%	4.48%	1.38%
Technical Analysis	100%	25%	6.97%	30.09%
Controversies	0%	0%	0%	0.19%
Macro	0%	0%	0%	28.71%

Earnings· May 4

Axsome Therapeutics reported Q1 2026 earnings with a revenue beat of $191.2M, a 57% year-over-year increase, but an adjusted EPS miss of $(1.26), down 85% year-over-year.
The company's strong revenue momentum is driven by Auvelity, with a major label expansion in Alzheimer's agitation expected to boost peak sales to $3-4B.
Axsome's cash burn and widening losses raise questions about the company's long-term prospects, despite a recent 20% price jump and strong institutional buying interest.

Analysts· Aug 10

Morgan Stanley downgraded Axsome Therapeutics to Equal-Weight, lowering the price target from $105 to $34.
Truist Securities maintained a Buy rating, but lowered the price target from $200 to $160.
Analysts remain confident in Axsome Therapeutics, with a 93% buy consensus, and multiple firms have maintained their Buy ratings despite lowering price targets.

Announcements· May 1

Axsome Therapeutics' Auvelity has received FDA approval for the treatment of agitation associated with dementia due to Alzheimer's disease.
This is a significant milestone, as Auvelity is the first non-antipsychotic treatment approved for this condition, addressing a major unmet need.
The approval has sent Axsome Therapeutics' stock price soaring, with a 12% increase in afternoon trading, and analysts projecting peak sales of over $2.1 billion.

Controversies· May 18

Glancy Prongay & Murray LLP, a securities fraud law firm, is investigating Axsome Therapeutics, Inc. (AXSM) on behalf of investors, suggesting potential legal action.
A video discusses Axsome Therapeutics Securities Class Action, providing information and explanations that may be helpful to investors.
The firm's investigation and the video's content may indicate ongoing controversy and potential issues surrounding Axsome Therapeutics, Inc. (AXSM).

Technical Analysis· Aug 22

$AXSM has shown a strong follow-through on its breakout, touching 64 from 55 and retesting.
The stock is currently sitting under the $60 whole number, which could be used as a pivot, and has seen high volume, including 10x average volume.
Technical indicators such as RSI, MACD, and MA200 are aligned, suggesting a potentially strong move to 67-70 area this week.

Generated by AI

Community

Of the messages about AXSM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	92.65%	90.02%	87.1%	58.99%
Newcomers	7.35%	9.98%	12.9%	41.01%

Regulars· Sep 29

Regular investors are expressing frustration with Axsome Therapeutics' management, citing volatility and lack of confidence in the company's multibillion-dollar franchise potential, and are calling for a buyback and better ADA data disclosure.
The stock's recent decline is being attributed to a combination of factors, including rotation out of pharma companies and a lack of visibility into revenue estimates for Auvelity, with some investors speculating that an offering may be imminent.
Despite the decline, some investors remain optimistic, citing the growth in institutional ownership, with institutions adding shares rather than exiting their positions, and are urging others to have faith in the system and be patient.

Newcomers· May 5

Many newcomers are excited about the 12% increase in stock price after the Q1 2026 financial results were announced.
Some are focusing on the company's Q1 2026 financial results and business update, noting a positive trend in the stock price after the announcement.
Others are highlighting the stock's high price level and active volume, suggesting that it is a strong biotech name to watch.

Generated by AI

Axsome Therapeutics

Social

Sep 29

Bullish· Sep 23

Bearish· May 4

Earnings· May 4

Analysts· Aug 10

Announcements· May 1

Controversies· May 18

Technical Analysis· Aug 22

Regulars· Sep 29

Newcomers· May 5

Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst

H.C. Wainwright reiterates Axsome stock Buy rating at $290 target

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Axsome Therapeutics (N

10 Health Care Stocks Whale Activity In Today’s Session - Oruka Therapeutics (NASDAQ:ORKA), Axsome Therap

Truist initiates Axsome stock coverage with buy rating on growth

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

Also Discussed

Axsome Therapeutics Inc

Company Information

Location

Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst

H.C. Wainwright reiterates Axsome stock Buy rating at $290 target

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Axsome Therapeutics (N

10 Health Care Stocks Whale Activity In Today’s Session - Oruka Therapeutics (NASDAQ:ORKA), Axsome Therap

Truist initiates Axsome stock coverage with buy rating on growth

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

Also Discussed

Social

Sep 29

Bullish· Sep 23

Bearish· May 4

Earnings· May 4

Analysts· Aug 10

Announcements· May 1

Controversies· May 18

Technical Analysis· Aug 22

Regulars· Sep 29

Newcomers· May 5